Simcere Ups Stake in Boda Pharma to 90%

Simcere Pharmaceutical (先声药业) announced a transaction that will increase its ownership of Boda Pharma to 90%. Boda makes Yidasheng, an injectable edaravone drug for management of stroke. Yidasheng complements Bicun, another injectable edaravone drug that is Simcere’s mainstay product. Simcere purchased its original 51% stake in Boda in September of 2007, paying $14.8 million. More details... Stock Symbol: (NYSE: SCR)